Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma

  • Sandra P. D’Angelo
    Department of Medicine, Weill Cornell Medical College, New York, New York
  • Jeffery Russell
    H. Lee Moffitt Cancer Center, Tampa, Florida
  • Céleste Lebbé
    Assistance Publique–Hôpitaux de Paris Dermatology and Centre d’Investigation Clinique, University Paris Diderot Institut National de la Santé et de la Recherche Medicale U976, Saint Louis Hospital, Paris, France
  • Bartosz Chmielowski
    Department of Medicine, UCLA (University of California, Los Angeles) Medical Center
  • Thilo Gambichler
    Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany
  • Jean-Jacques Grob
    Department of Dermatology, Venerology, and Cutaneous Oncology, Aix-Marseille University, Assistance Publique–Hôpitaux de Marseille, Timone Hospital, Marseille, France
  • Felix Kiecker
    Department of Dermatology, Venereology, and Allergology, Charité Universitätsmedizin Berlin, Edmund-Lesser-Haus, Berlin, Germany
  • Guilherme Rabinowits
    Dana-Farber Cancer Institute, Boston, Massachusetts
  • Patrick Terheyden
    Department of Dermatology, Allergology, and Venereology, University of Lübeck, Lübeck, Germany
  • Isabella Zwiener
    Merck KGaA, Darmstadt, Germany
  • Marcis Bajars
    EMD Serono, Billerica, Massachusetts
  • Meliessa Hennessy
    EMD Serono, Billerica, Massachusetts
  • Howard L. Kaufman
    Rutgers Cancer Institute of New Jersey, New Brunswick

書誌事項

タイトル別名
  • A Preplanned Interim Analysis of a Clinical Trial

この論文をさがす

収録刊行物

  • JAMA Oncology

    JAMA Oncology 4 (9), e180077-, 2018-09-13

    American Medical Association (AMA)

被引用文献 (4)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ